AI-driven biologics platform: antibodies, bispecifics, full-stack discovery with 40+ programs; HXN-1001 in Phase 2; Sanofi (autoimmune/inflammatory) and WuXi XDC partnerships
No detailed funding rounds available.
Total known funding: